开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2024-08-26 ms9000001272921253 来自福建省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：细胞治疗;肿瘤免疫
经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof.

21 0

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2024-04-13 国统乃我辈之愿来自海南省

去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗

70 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2023-12-24 ms2000001657204792 来自上海

一个月了，还在邀请审稿人，要是还邀请不到真开始慌了

98 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2024-04-05 罗磊来自湖北省

审稿速度:1.0
经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收

105 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2023-12-21 39314679eccv 来自湖北省

这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？

85 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2023-11-07 1226054bm42暂无昵称来自广东省

审稿速度:6.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;Meta分析
经验分享：投稿的一篇Meta分析
6月1号投稿
6月3号送审
10月30号返修
11月1号修回
11月7号接收
外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错

80 0

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2023-10-16 仅叹来自重庆

投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。
——————No.1——————
2022.9.30 submission received
2022.9.30 reviewers invited (21)
2022.12.28 reviewers invited (22)
2023.1.10 无审稿人接受审稿邀请→rejected
——————No.2——————
2023.5.17 submission received
2023.5.18 reviewers invited (27)
2023.5.25 one reviewer accepted to review
2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿

93 0

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2023-07-04 国统乃我辈之愿来自海南省

偏重的研究方向：临床实验研究
经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！

104 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2023-07-05 采药者来自广东省

审稿速度:4.0
偏重的研究方向：临床实验研究
经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！

124 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2222504, encodeId=e76822225042f, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：细胞治疗;肿瘤免疫 经验分享：2024.7.15转投，2024.7.30审稿意见，小修，3个问题。8.8修回。8.18接受。8.22proof., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8276393384, createdName=ms9000001272921253, createdTime=Mon Aug 26 17:40:47 CST 2024, time=2024-08-26, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2198236, encodeId=85ee2198236c6, content=去年6月投的还是非oa，不要版面费，昨天投了一篇，怎么都成oa了吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=70, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Sat Apr 13 00:53:35 CST 2024, time=2024-04-13, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2176786, encodeId=3c4c21e678694, content=一个月了，还在邀请审稿人，要是还邀请不到真开始慌了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29518143298, createdName=ms2000001657204792, createdTime=Sun Dec 24 06:28:33 CST 2023, time=2023-12-24, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2197011, encodeId=61d0219e011ed, content=审稿速度:1.0 经验分享：写的小分子RNA关于肿瘤的综述，投稿十天就返修了，希望顺利接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e461972408, createdName=罗磊, createdTime=Fri Apr 05 10:37:11 CST 2024, time=2024-04-05, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2176388, encodeId=37a421e6388c8, content=这个杂志现在好像停止proof了？因为要全面开放剔除非OA？还是本来就这么慢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=85, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=78895478849, createdName=39314679eccv, createdTime=Thu Dec 21 20:22:48 CST 2023, time=2023-12-21, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2167299, encodeId=fc5c216e2991c, content=审稿速度:6.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;Meta分析 经验分享：投稿的一篇Meta分析 6月1号投稿 6月3号送审 10月30号返修 11月1号修回 11月7号接收 外审期间多次联系编辑，编辑都很耐心回复，总体来说还不错, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7bed2326866, createdName=1226054bm42暂无昵称, createdTime=Tue Nov 07 23:34:59 CST 2023, time=2023-11-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2163007, encodeId=fb13216300ed2, content=投稿过2篇，均因无审稿意见而在投稿3+月后拒稿，浪费时间！建议慎投。 ——————No.1—————— 2022.9.30 submission received 2022.9.30 reviewers invited (21) 2022.12.28 reviewers invited (22) 2023.1.10 无审稿人接受审稿邀请→rejected ——————No.2—————— 2023.5.17 submission received 2023.5.18 reviewers invited (27) 2023.5.25 one reviewer accepted to review 2023.8.27 只找到一个审稿人，并且一直没返回审稿意见→拒稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0bf15495921, createdName=仅叹, createdTime=Mon Oct 16 10:12:33 CST 2023, time=2023-10-16, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2146282, encodeId=58fd214628293, content=偏重的研究方向：临床实验研究 经验分享：4.10号投稿，5.13邀请审稿人，5.21审稿意见收到，6.5号修回，6.14接受，6.24号pubmed检索，预计7.10号wos可检索！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=104, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ae372438623, createdName=国统乃我辈之愿, createdTime=Tue Jul 04 15:12:17 CST 2023, time=2023-07-04, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=2146366, encodeId=d424214636621, content=审稿速度:4.0 偏重的研究方向：临床实验研究 经验分享：投稿六个多月了，一审已经半年了还没有回信，中间催了一次，客套回复了一下，后来又问了一次，才知道找了24个审稿人，只有一个接受，然后半年没给出意见，半年了也没找新的审稿人，也不去催那个审稿人，无语了！唯一的希望就是告诉我已经电话联系了一个审稿人！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201104/e110baa6574e4220b15f12b12f7dc820/6b425004735845a2b3f1adb56a948307.jpg, createdBy=7ec95239393, createdName=采药者, createdTime=Wed Jul 05 01:44:05 CST 2023, time=2023-07-05, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2149779, encodeId=55df2149e79b1, content=审稿速度:6.0 经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28756404390, createdName=ms9000001799259170, createdTime=Tue Jul 25 17:56:44 CST 2023, time=2023-07-25, status=1, ipAttribution=云南省)]

2023-07-25 ms9000001799259170 来自云南省

审稿速度:6.0
经验分享：谨慎投稿！投稿三个多月毫无动静，最后发邮件给了拒稿，说找不到审稿人真想骂人

134 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务